Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's lymphoma

Bone Marrow Transplantation

Volumn 31, Issue 11, 2003, Pages 1009-1013

  Gordan, L N ^a   Sugrue, M W ^b   Lynch, J W ^a   Williams, K D ^b   Khan, S A ^a   Moreb, J S ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Autografting; Lymphocyte recovery; Lymphoma; Stem cell transplant

Indexed keywords

BUSULFAN; CARBOPLATIN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; ETOPOSIDE; THIOTEPA;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; LENGTH OF STAY; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; LYMPHOCYTE DEPLETION; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 0037671556     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704050     Document Type: Article

References (18)

1. Cabanillas F, Hagemeister FB, Bodey GP et al. IMVP16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982; 60: 693-697.
2. Cabanillas F, Hagermeister FB, McLaughlin P et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 1987; 3: 407-412.
3. Velasquez WS, Cabanillas F, Salvadore P et al. Effective salvage therapy for lymphoma with cisplatin in combination with high dose Ara C and dexamethasone (DHAP). Blood 1988; 71: 117-122.
4. Philip T, Armitage JO, Spitzer G et al. High dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316: 1493-1498.
5. Philip T, Hartman O, Biron P et al. High dose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin's lymphoma. J Clin Oncol 1988; 6: 1118-1124.
6. Philip T, Guglielmi C, Hagenbeek A et al. A prospective randomized study comparing autologous bone marrow transplantation (ABMT) and salvage chemotherapy (DHAP) in sensitive-relapse of non-Hodgkin's lymphoma (NHL): final analysis of the PARMA study. N Engl J Med 1991; 333: 1540-1545.
7. Bosly A, Coiffier B, Gisselbrecht C et al. For the Groupe d'Etude des Lymphomes Agressifs. Bone marrow transplantation significantly prolongs survival after relapse in aggressive lymphoma patients treated with the LNH84 regimen. J Clin Oncol 1992; 10: 1615-1623.
8. Powles R, Singhai S, Treleaven J et al. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood 1998; 91: 3481-3486.
9. Pavletic ZS, Joshi SS, Piruccello SJ et al. Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematological malignancies. Bone Marrow Transplant 1998; 21: 33-41.
10. Porrata LF, Gertz MA, Inwards DJ et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma and non-Hodgkin lymphoma. Blood 2001; 98: 579-585.
11. Sugrue MW, Williams K, Pollock BH et al. Characterization and outcome of 'hard to mobilize' lymphoma patients undergoing autologous stem cell transplantation. Leukemia Lymphoma 2000; 39: 509-519.
12. Barrett AJ, Ringden O, Zhang MJ et al. Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. Blood 2000; 95: 3323-3327.
13. Guillaume T, Rubinstein DB, Symann M et al. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 1998; 92: 1471-1990.
14. Storek J, Ferrara S, Ku N et al. B cell reconstitution after human bone marrow transplantation: recapitulation of ontogeny? Bone Marrow Transplant 1993; 12: 387-398.
15. Bengtsson M, Smedmyr B, Festin R et al. B lymphocyte regeneration in marrow and blood after autologous bone marrow transplantation: Increased numbers of B cells carrying activation and progression markers. Leukemia Res 1989; 13: 791-797.
16. Small TN, Keever CA, Weiner-Fedus S et al. B-cell differentiation following autologous, conventional, or T-cell depleted bone marrow transplantation: a recapitulation of normal B-cell ontogeny. Blood 1990; 76: 1647-1656.
17. Leitenberg D, Rappeport JN, Smith BR. B-cell precursor bone marrow reconstitution after bone marrow transplantation. Am J Clin Pathol 1994; 102: 231-236.
18. Bengtsson M, Totterman TH, Smedmyr B et al. Regeneration of functional and activated NK and T subset cells in the marrow and blood after autologous bone marrow transplantation: a prospective phenotypic study with 2/3 color FACS analysis. Leukemia 1989; 3: 68-75.